• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在一项17中心病例对照研究中,大环内酯类药物的使用被确定为耐大环内酯类肺炎链球菌的危险因素。

Macrolide use identified as risk factor for macrolide-resistant Streptococcus pneumoniae in a 17-center case-control study.

作者信息

Beekmann S E, Diekema D J, Heilmann K P, Richter S S, Doern G V

机构信息

Division of Medical Microbiology, Department of Pathology 265 MRC, University of Iowa, Iowa, IA, 52242, USA.

出版信息

Eur J Clin Microbiol Infect Dis. 2006 May;25(5):335-9. doi: 10.1007/s10096-006-0137-8.

DOI:10.1007/s10096-006-0137-8
PMID:16612609
Abstract

The objective of the case-control study presented here was to examine the risk factors for macrolide-resistant Streptococcus pneumoniae. As part of a 44-center U.S. surveillance study, 1,817 unique isolates of S. pneumoniae were collected from November 2002 through April 2003. Seventy-five randomly selected macrolide-resistant isolates (cases) were each matched with one susceptible control. Macrolide use in the 6 weeks prior to sample collection was reported for seven cases and one control. The final conditional logistic regression model identified two statistically significant variables: a history of alcohol abuse was protective, while macrolide use in the 6 weeks prior to sample collection was a significant risk factor for macrolide-resistant S. pneumoniae. Macrolide resistance was associated with use of any antibiotic during the prior 6 weeks, and was most strongly associated with previous macrolide use.

摘要

此处呈现的病例对照研究的目的是检验耐大环内酯类肺炎链球菌的风险因素。作为美国一项44中心监测研究的一部分,2002年11月至2003年4月期间收集了1817株独特的肺炎链球菌分离株。随机选择75株耐大环内酯类分离株(病例),每株与一株敏感对照进行匹配。报告了7例病例和1例对照在样本采集前6周内使用大环内酯类药物的情况。最终的条件逻辑回归模型确定了两个具有统计学意义的变量:酗酒史具有保护作用,而样本采集前6周内使用大环内酯类药物是耐大环内酯类肺炎链球菌的一个显著风险因素。大环内酯类耐药与前6周内使用任何抗生素有关,且与之前使用大环内酯类药物的关联最为密切。

相似文献

1
Macrolide use identified as risk factor for macrolide-resistant Streptococcus pneumoniae in a 17-center case-control study.在一项17中心病例对照研究中,大环内酯类药物的使用被确定为耐大环内酯类肺炎链球菌的危险因素。
Eur J Clin Microbiol Infect Dis. 2006 May;25(5):335-9. doi: 10.1007/s10096-006-0137-8.
2
Macrolide resistance among middle ear isolates of Streptococcus pneumoniae observed at eight United States pediatric centers: prevalence of M and MLSB phenotypes.在美国八个儿科中心观察到的肺炎链球菌中耳分离株中的大环内酯耐药性:M型和MLSB表型的患病率
Pediatr Infect Dis J. 2003 Jul;22(7):623-7. doi: 10.1097/01.inf.0000073124.06415.93.
3
Lack of correlation between reduced outpatient consumption of macrolides and macrolide resistance of invasive Streptococcus pneumoniae isolates in Slovenia during 1997-2017.1997 年至 2017 年期间斯洛文尼亚门诊大环内酯类药物使用量减少与侵袭性肺炎链球菌分离株大环内酯类耐药性之间无相关性。
J Glob Antimicrob Resist. 2019 Mar;16:242-248. doi: 10.1016/j.jgar.2018.10.022. Epub 2018 Nov 1.
4
Genotypic characterization of macrolide-resistant strains of Streptococcus pneumoniae isolated in Quebec, Canada, and in vitro activity of ABT-773 and telithromycin.加拿大魁北克分离出的肺炎链球菌大环内酯类耐药菌株的基因型特征以及ABT-773和泰利霉素的体外活性
J Antimicrob Chemother. 2002 Sep;50(3):403-6. doi: 10.1093/jac/dkf146.
5
A review of clinical failures associated with macrolide-resistant Streptococcus pneumoniae.与耐大环内酯类肺炎链球菌相关的临床失败病例综述。
Int J Antimicrob Agents. 2004 Aug;24(2):95-104. doi: 10.1016/j.ijantimicag.2004.03.008.
6
Phenotypic and genotypic characterization of Streptococcus pneumoniae resistant to macrolide in Casablanca, Morocco.摩洛哥卡萨布兰卡对大环内酯类耐药的肺炎链球菌的表型和基因型特征
Infect Genet Evol. 2016 Jun;40:200-204. doi: 10.1016/j.meegid.2016.03.003. Epub 2016 Mar 4.
7
Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000-2003: PROTEKT US years 1-3.2000 - 2003年美国分离出的肺炎链球菌的抗菌耐药性趋势:PROTEKT美国研究的第1 - 3年。
J Infect. 2005 Dec;51(5):355-63. doi: 10.1016/j.jinf.2005.04.015. Epub 2005 Jun 13.
8
Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002.从呼吸道感染患者中分离出的肺炎链球菌菌株对大环内酯类药物的耐药性及耐药机制在美国的分布情况:2001 - 2002年美国肺炎链球菌耐药性监测研究(PROTEKT US)
J Antimicrob Chemother. 2004 Aug;54 Suppl 1:i17-22. doi: 10.1093/jac/dkh312.
9
Macrolide resistance among invasive Streptococcus pneumoniae isolates.侵袭性肺炎链球菌分离株中的大环内酯类耐药性
JAMA. 2001 Oct 17;286(15):1857-62. doi: 10.1001/jama.286.15.1857.
10
Correlation between usage of macrolide antibiotic and resistance of Streptococcus pneumoniae clinic isolates from Chongqing children's hospital.重庆儿童医院肺炎链球菌临床分离株大环内酯类抗生素使用情况与耐药性的相关性
Pediatr Pulmonol. 2009 Sep;44(9):917-21. doi: 10.1002/ppul.21081.

引用本文的文献

1
Beta-lactam versus beta- lactam/macrolide therapy in pediatric outpatient pneumonia.β-内酰胺类药物与β-内酰胺类/大环内酯类药物治疗小儿门诊肺炎的对比
Pediatr Pulmonol. 2016 May;51(5):541-8. doi: 10.1002/ppul.23312. Epub 2015 Sep 14.
2
Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance.研究抗生素使用对耐药性影响的流行病学解释。
Clin Microbiol Rev. 2013 Apr;26(2):289-307. doi: 10.1128/CMR.00001-13.
3
Antimicrobial agent exposure and the emergence and spread of resistant microorganisms: issues associated with study design.

本文引用的文献

1
Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes?美国肺炎链球菌的抗菌药物耐药性:我们是否已开始在某些抗菌药物类别的耐药性问题上有所转机?
Clin Infect Dis. 2005 Jul 15;41(2):139-48. doi: 10.1086/430906. Epub 2005 Jun 7.
2
Community prescribing and resistant Streptococcus pneumoniae.社区处方与耐肺炎链球菌
Emerg Infect Dis. 2005 Jun;11(6):829-37. doi: 10.3201/eid1106.050198.
3
Hidden epidemic of macrolide-resistant pneumococci.
抗菌药物暴露与耐药微生物的出现和传播:与研究设计相关的问题。
Eur J Clin Microbiol Infect Dis. 2013 May;32(5):581-95. doi: 10.1007/s10096-012-1795-3. Epub 2012 Dec 27.
大环内酯类耐药肺炎球菌的隐匿性流行
Emerg Infect Dis. 2005 Jun;11(6):802-7. doi: 10.3201/eid1106.050147.
4
Predicting antimicrobial resistance in invasive pneumococcal infections.预测侵袭性肺炎球菌感染中的抗菌药物耐药性。
Clin Infect Dis. 2005 May 1;40(9):1288-97. doi: 10.1086/429242. Epub 2005 Mar 31.
5
Reference group choice and antibiotic resistance outcomes.参照组的选择与抗生素耐药性结果
Emerg Infect Dis. 2004 Jun;10(6):1125-8. doi: 10.3201/eid1006.020665.
6
Predicting the emergence of antimicrobial resistance.预测抗菌药物耐药性的出现。
Clin Infect Dis. 2002 May 15;34(10):1418; author reply 1418. doi: 10.1086/339943.
7
Risk factors for penicillin resistance and mortality in Korean adults with Streptococcus pneumoniae bacteremia.
Eur J Clin Microbiol Infect Dis. 2002 Jan;21(1):35-42. doi: 10.1007/s10096-001-0650-8.
8
Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniae.肺炎链球菌抗生素使用的局部差异以及红霉素和青霉素耐药性的地理差异的重要性。
J Clin Microbiol. 2002 Jan;40(1):159-64. doi: 10.1128/JCM.40.1.159-164.2002.
9
Influence of macrolide antibiotics on promotion of resistance in the oral flora of children.大环内酯类抗生素对儿童口腔菌群耐药性增强的影响。
Infection. 2001 Oct;29(5):251-6. doi: 10.1007/s15010-001-1072-3.
10
Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States.美国肺炎链球菌的抗菌药物使用情况及抗菌药物耐药性的出现
Clin Infect Dis. 2001 Sep 15;33 Suppl 3:S187-92. doi: 10.1086/321847.